Expasy logo

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot Q9ULV1: Variant p.Arg417Gln

Frizzled-4
Gene: FZD4
Feedback?
Variant information Variant position: help 417 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: help LP/P [Disclaimer] The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance
Residue change: help From Arginine (R) to Glutamine (Q) at position 417 (R417Q, p.Arg417Gln). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: help Change from large size and basic (R) to medium size and polar (Q) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: help 1 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page
Variant description: help In EVR1; 48% loss of its wild-type activity; associated in a EVR4 patient with mutation Cys-444 in LPR5. Any additional useful information about the variant.
Other resources: help Links to websites of interest for the variant.


Sequence information Variant position: help 417 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: help 537 The length of the canonical sequence.
Location on the sequence: help TYLVIGTLFIAAGLVALFKI R SNLQKDGTKTDKLERLMVKI The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: help The multiple alignment of the region surrounding the variant against various orthologous sequences. 
Human                         TYLVIGTLFIAAGLVALFKIRSNLQKDGTKTDKLERLMVKI

Mouse                         TYLVIGTLFIAAGLVALFKIRSNLQKDGTKTDKLERLMVKI

Rat                           TYLVIGTLFIAAGLVALFKIRSNLQKDGTKTDKLERLMVKI

Chicken                       TYLVIGTLFIAAGLVALFKIRSNLQKDGTKTDKLERLMVKI

Xenopus laevis                TYLVIGTLFIAAGLVALFKIRSNLQKDGTKTDKLERLMVKI
Sequence annotation in neighborhood: help The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.
TypePositionsDescription
Chain 37 – 537 Frizzled-4
Transmembrane 384 – 418 Helical; Name=5
Mutagenesis 399 – 399 L -> F. No effect on signaling activity.
Mutagenesis 418 – 418 S -> N. Increased signaling activity.
Helix 392 – 417



Literature citations
Frizzled 4 gene (FZD4) mutations in patients with familial exudative vitreoretinopathy with variable expressivity.
Kondo H.; Hayashi H.; Oshima K.; Tahira T.; Hayashi K.;
Br. J. Ophthalmol. 87:1291-1295(2003)
Cited for: VARIANTS EVR1 TYR-69; VAL-105; GLN-417 AND ASP-488; Complexity of the genotype-phenotype correlation in familial exudative vitreoretinopathy with mutations in the LRP5 and/or FZD4 genes.
Qin M.; Hayashi H.; Oshima K.; Tahira T.; Hayashi K.; Kondo H.;
Hum. Mutat. 26:104-112(2005)
Cited for: VARIANTS EVR1 TYR-69; VAL-105; CYS-335; VAL-342; GLN-417 AND ASP-488; Moderate reduction of Norrin signaling activity associated with the causative missense mutations identified in patients with familial exudative vitreoretinopathy.
Qin M.; Kondo H.; Tahira T.; Hayashi K.;
Hum. Genet. 122:615-623(2008)
Cited for: CHARACTERIZATION OF VARIANTS EVR1 VAL-105 AND GLN-417; CHARACTERIZATION OF VARIANT TYR-69;
Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.